SQ-LIP-000008 · v1.3 (archived) · View current version →
Is lipedema associated with fibromyalgia and other chronic-pain conditions?
Based on currently indexed evidence, lipedema is consistently associated with chronic pain and frequently co-occurs with fibromyalgia, though all data are observational and largely cross-sectional. Multiple cross-sectional studies using ACR 2016 diagnostic criteria report fibromyalgia prevalence of approximately 34–35% among women with lipedema (DOI:10.1089/lrb.2023.0038; DOI:10.2147/jpr.s315736), and those meeting fibromyalgia criteria had significantly higher anxiety, depression, and impaired quality of life; conversely, an earlier study found lipedema in 50% of women already meeting ACR fibromyalgia criteria (DOI:10.1177/02683555251321042). Pain burden in lipedema is substantial: 100% of lipedema patients in one controlled study reported pain versus 70.8% of matched controls, with 43.2% reporting severe pain-related disability versus 9.2% of controls, and pain severity correlated strongly with depressive symptoms (rho≈0.61) (DOI:10.3390/life14030295). Musculoskeletal involvement is common, with knee/joint pain reported by ~58% of affected women (DOI:10.1590/1677-5449.202101981; DOI:10.1111/ddg.15064). In a large cohort of 860 patients, 99% had at least one comorbidity, including joint pain (58%), migraine (35%), and insomnia (36%), though fibromyalgia was not separately enumerated (DOI:10.1111/ddg.15064). Mechanistically, one cross-sectional study found pain prevalence and von Frey cutaneous hypersensitivity increased with disease stage (60–100% leg pain; painDETECT >19 only in Stage 3), with reduced dermal Tuj-1+ neuronal density and elevated CGRP/NGF in Stage 3 tissues, suggesting peripheral neuropathic pain and neurogenic inflammation independent of BMI (DOI:10.3390/ijms231810313). Additional chronic-pain-related features include fatigue (~75%), hypermobility (>50%), and psychosocial distress. Most evidence is low-to-moderate quality with moderate-to-unknown risk of bias; causal direction and whether shared mechanisms underlie the co-occurrence remain unestablished.
Knowledge freshness = share of the 9 indexed evidence sources from the last 5 years (newest 2025, oldest 2018) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
This update added a mechanistic cross-sectional study showing stage-dependent cutaneous hypersensitivity, reduced dermal neuronal density, and elevated CGRP/NGF, characterizing lipedema pain as peripheral neuropathic/neurogenic-inflammatory and independent of BMI.
Supporting claims
- SCR-LIP-000021 supporting
Lipedema and fibromyalgia frequently co-occur: a cross-sectional study found lipedema in 50% of women meeting ACR fibromyalgia criteria, with longer fibromyalgia diagnostic delay and younger menarche as risk factors.
Lipedema awareness in fibromyalgia — Bolkan Günaydın et al. (2025) - SCR-LIP-000022 supporting
Knee pain is a common musculoskeletal feature of lipedema, reported by 58.1% of women screening positive for lipedema in a Brazilian population study.
Prevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022) - SCR-LIP-000104 supporting
In a cross-sectional survey of 354 women with lipedema, 35% (124/354) met ACR 2016 diagnostic criteria for fibromyalgia syndrome, and those with fibromyalgia had significantly higher anxiety, depression, and impaired quality of life compared to those without.
Prevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life — Cagliyan Turk et al. (2024) · Common and Contrasting Characteristics of the Chronic Soft-Tissue Pain Conditions Fibromyalgia and Lipedema — Angst et al. (2021) - SCR-LIP-000105 supporting
In a cross-sectional study comparing lipedema patients to sex-, age-, and BMI-matched population controls, 100% of lipedema patients reported pain (vs. 70.8% of controls), with 43.2% reporting severe pain-related disability in daily activities vs. 9.2% of controls, and strong correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
Health Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls — Kempa et al. (2024)
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000058 context
The article discusses the effects of a modified Mediterranean diet on lipoedema patients, noting improvements in their ability to perform daily activities with less fatigue, pain, and anxiety, but does not directly establish a link between lipoedema and fibromyalgia or other chronic-pain conditions.
Potential Effects of a Modified Mediterranean Diet on Body Composition in Lipoedema — Di Renzo et al. (2021) - SCR-LIP-000106 context
In a cohort of 860 lipedema patients, 99% had at least one comorbidity, including joint pain (58%), abnormal menstruation (43%), insomnia (36%), migraine (35%), allergies (33%), depression (31%), and lymphedema (30%), but fibromyalgia was not specifically reported among the listed comorbidities.
Breaking the circle‐effectiveness of liposuction in lipedema — Seefeldt et al. (2023) - SCR-LIP-000107 context
Lipedema is characterized as a painful fat disorder associated with fatigue (reported by ~75% of patients), joint abnormalities, psychosocial distress, and hypermobility in >50% of patients, but the article does not specifically quantify co-occurrence with fibromyalgia or other named chronic-pain conditions.
Lipedema: friend and foe — Torre et al. (2018) - SCR-LIP-000147 refines
In lipedema patients, pain prevalence and von Frey cutaneous hypersensitivity increased with disease stage (60-100% leg pain across stages, painDETECT >19 only in Stage 3), with reduced dermal Tuj-1+ neuronal density in abdomen and elevated CGRP/NGF in Stage 3 tissues suggesting peripheral neuropathic pain and neurogenic inflammation, independent of BMI.
Indications of Peripheral Pain, Dermal Hypersensitivity, and Neurogenic Inflammation in Patients with Lipedema — Chakraborty et al. (2022)
Major uncertainty
All indexed evidence is observational and largely cross-sectional (low-to-moderate quality, moderate/unknown risk of bias), so the causal direction, whether fibromyalgia and lipedema share common pathophysiology, and whether the observed peripheral neuropathic/neurogenic-inflammation mechanisms in lipedema overlap with or are distinct from fibromyalgia's central-sensitization mechanisms remain unresolved.
Version history
- SQ-LIP-000008 · v1.3 — 2026-05-31 — This update added a mechanistic cross-sectional study showing stage-dependent cutaneous hypersensitivity, reduced dermal neuronal density, and elevated CGRP/NGF, characterizing lipedema pain as peripheral neuropathic/neurogenic-inflammatory and independent of BMI. · view this version
- SQ-LIP-000008 · v1.2 — 2026-05-31 — This update added multiple cross-sectional studies with validated diagnostic criteria that quantified fibromyalgia comorbidity at 34–35% in lipedema populations, documented that 100% of lipedema patients report pain versus matched controls, and provided large-cohort comorbidity data, substantially strengthening and numerically grounding the previously approximate estimate of 'about half' and clarifying that the earlier figure likely reflected a fibromyalgia-enriched sample. · view this version
- SQ-LIP-000008 · v1.1 — 2026-05-30 — This update added context regarding the effects of a modified Mediterranean diet on lipoedema patients, noting improvements in daily activities and pain but not establishing a direct link to fibromyalgia. Answer reviewed and tightened by curator for rigor. · view this version
- SQ-LIP-000008 · v1.0 — 2026-05-30 — founding index (8 claims) · view this version
Key references
DOI:10.1177/02683555251321042 · DOI:10.1590/1677-5449.202101981 · DOI:10.3390/nu13020358 · DOI:10.1089/lrb.2023.0038 · DOI:10.2147/jpr.s315736 · DOI:10.3390/life14030295 · DOI:10.1111/ddg.15064 · DOI:10.1515/hmbci-2017-0076 · DOI:10.3390/ijms231810313